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SI Materials and Methods
Flow Cytometry. hCCR5 and hCD4 surface expression on 293T cells
was conﬁrmed by ﬂow cytometry using an LSRFortessa cytometer
(BDBiosciences). Cells were stainedwith ﬂuorescein isothiocyanate
(FITC) mouse anti-human CD195 (CCR5) (BD Pharmingen) and
allophycocyanin (APC) mouse anti-human CD4 (BD Pharmingen)
according to manufacturer’s instructions. Data were analyzed using
FlowJo software (Treestar).
Production of Recombinant Adenoviruses. Adenoviral stocks were
generated as previously described (1). Brieﬂy, AdV-hCCR5-2A-
hCD4 (AdV serotype 5) was transfected into HEK293 cells
(ATCC) using the calcium-phosphate method. At full cytophatic
effects, transfected cultures were harvested and freeze–thawed.
Supernatants were serially passaged two more times. For virus
puriﬁcation, cell pellets were resuspended in 0.01 M sodium
phosphate buffer (pH 7.2) and lysed in 5% sodium deoxycholate,
followed by DNase I digestion. Lysates were centrifuged and the
supernatant was layered onto a 1.2- to 1.46-g/mL−1 CsCl gradi-
ent, then spun at 95,133 × g on a Beckman Optima 100K-Ultra
centrifuge using an SW28 spinning-bucket rotor (Beckman-
Coulter). Adenovirus bands were isolated and further puriﬁed
on a second CsCl gradient using an SW41.Ti spinning-bucket
rotor. Resulting puriﬁed adenoviral bands were isolated and
twice dialyzed against 4% (wt/vol) sucrose. Adenovirus concen-
trations were determined at 1012 times the OD260 reading on
a FLUOstar Omega plate reader (BMG Labtech). Adenovirus
stocks were aliquoted and stored at −80 °C. For in vivo trans-
duction, 1011 particles were injected through the lateral tail vein.
HIV Pseudovirus Production and in Vivo Infection. HIVYU-2 pseu-
dovirus was generated by cotransfection of pTRIPcre [nls-cre
cloned into pTRIP (2, 3) using XbaI/XhoI sites], HIV gag-pol
(4), and pSVIIIenvYU-2 (5) in HEK293T cells (ATCC) using X-
tremeGENE 9 (Roche) according to the manufacturer’s in-
structions. Plasmids were transfected at a 1.42:1:1.68 ratio
(pTRIPcre:HIV gag-pol:pSVIIIenvYU-2). Pooled supernatants
were clariﬁed by centrifugation at 300 × g, ﬁltered through
a 0.45-μm ﬁlter unit (Thermo Scientiﬁc) to remove cell debris
and concentrated 20-fold using a stirred cell (Millipore) with
a 300,000 nominal molecular weight limit (NMWL) cutoff
membrane. Viral preparations were quantiﬁed using a p24
ELISA kit (PerkinElmer) according to manufacturer’s in-
struction. For in vivo infection, 500 μL of concentrated pseu-
dovirus (cp24 = 1.835 ± 0.3918 μg mL−1, mean ± SEM) were
injected through the lateral tail vein.
Histological Detection of hCCR5 and hCD4. Livers of mice injected
with AdV-hCCR5-2A-hCD4 were harvested 24 h after infection
and ﬁxed in 4% (vol/vol) paraformaldehyde, 10% (wt/vol) sucrose
for 1 h at 4 °C, followed by incubation in 30% (wt/vol) sucrose
overnight at 4 °C. Tissue was frozen in optimal cutting temper-
ature compound (Ted Pella, Inc.) at −80 °C. Tissue sections (8
μm) were cut on Superfrost Plus microscope slides (Fisher Sci-
entiﬁc). Sections were immunostained with phycoerythrin (PE)
mouse anti-human CD4 and FITC mouse anti-human CCR5
(both BD Pharmingen). Nuclei were detected using ProLong
Gold + DAPI (Invitrogen). Images were captured on an Axio-
plan 2 imaging ﬂuorescence microscope (Zeiss) using Metavue
Software (Molecular Devices) and processed in ImageJ (Na-
tional Institutes of Health).
Serum Antibody ELISA. ELISA plates (Corning) were coated with
goat anti-human IgG (Jackson ImmunoResearch Laboratories)
at 2.5 μg mL−1 overnight. Plates were blocked with 2 mM EDTA
and 0.05% Tween-20 in PBS (blocking buffer) for 1 h at room
temperature. Serial dilutions of mouse serum in PBS were in-
cubated and detected with an HRP-conjugated goat anti-human
IgG (Jackson ImmunoResearch Laboratories) at a 1:1,000 di-
lution in blocking buffer. Samples were subsequently developed
with ABTS [2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid)] (Invitrogen). Puriﬁed human IgG was included to gener-
ate the standard curve.
Bioluminescence Imaging.Mice were injected with 1011 adenoviral
particles i.v. and mAbs s.c. 24 h before i.v. injection with HIVYU-2
pseudovirus. At day 4 after pseudovirus infection mice were
anesthetized with 2% (vol/vol) isoﬂurane and injected i.p. with 4.5
mg D-Luciferin (Caliper Life Sciences). Bioluminescence was ac-
quired using an IVIS Lumina II platform (Caliper Life Sciences).
Neutralization Assays. TZM-bl neutralization screens were per-
formed as previously described (6).
Brieﬂy, neutralization was detected as reduction in luciferase
reporter gene expression after single round infection in Tzm.bl
cells. Murine leukemia virus was used as a negative control.
Recombinant Protein Expression and Puriﬁcation. Recombinant
proteins were expressed in HEK293T cells (ATCC). Human
monoclonal antibodies were puriﬁed using Protein G Sepharose 4
Fast Flow (GE Healthcare) as previously described (7). Anti-
bodies were dialyzed against PBS and sterile ﬁltered (0.22 μm).
Endotoxin (LPS) contamination was quantiﬁed by the Limulus
amebocyte lysate assay (Associates of Cape Cod) and levels were
<0.005 EU mg−1. His-tagged recombinant proteins were puriﬁed
using His-Tag isolation and pull-down dynabeads (Invitrogen).
Purity was assessed by SDS/PAGE and Coomassie staining and
was estimated to be >90%.
Site-Directed Mutagenesis. G236R/L328R mutations of the hIgG1
constant region were introduced using the QuikChange site-di-
rected mutagenesis Kit II (Agilent Technologies). For the in-
troduction of the G236R mutation the following primer pairs
were used: forward: 5′-GCACCTGAACTCCTGAGGGGACC-
GTCAGTCTTCCTC; reverse: 5′-GAGGAAGACTGACGGT-
CCCCTCAGGAGTTCAGGTGC. For the L328R mutation:
forward: 5′-GGTCTCCAACAAAGCCCGCCCAGCCCCCAT-
CGAG; reverse: 5′-CTCGATGGGGGCTGGGCGGGCTTT-
GTTGGAGACC. Mutated plasmid sequences were validated by
direct sequencing (Genewiz).
gp140 ELISA. Recombinant gp140 (8) (50 ng per well) was im-
mobilized onto high-binding 96-well microtiter plates (Nunc).
After blocking with PBS + 2% (wt/vol) BSA + 0.05% Tween 20
for 2 h, plates were incubated for 1 h with serially diluted IgG
antibodies in PBS, followed by HRP-conjugated goat anti-human
IgG (1 h; 1:5,000; Sigma). Plates were developed using the
3,3′,5,5′-Tetramethylbenzidine (TMB) two-component peroxi-
dase substrate kit (KPL).
Surface Plasmon Resonance. All experiments were performed with
a Biacore T100 SPR system (Biacore, GE Healthcare) at 25 °C in
HBS-EP+ buffer [10 mM Hepes (pH 7.4), 150 mM NaCl,
3.4 mM EDTA, and 0.005% (vol/vol) surfactant P20]. For the
determination of the afﬁnity of mouse FcγRs for human IgG1
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and Fc domain variants, soluble ectodomains of mouse FcγRI,
FcγRII, FcγRIII, and FcγRIV diluted at 20 μg mL−1 in 10 mM
sodium acetate (pH 4.5, or pH 5 for FcγRI) were immobilized on
Series S CM5 chips by amine coupling, resulting in a density of
2,000 response units (RU). Recombinant IgG samples were in-
jected through ﬂow cells at seven different concentrations
(ranging from 2,000 to 31.25 nM; 1:2 successive dilutions) at
a ﬂow rate of 30 μL min−1 for 120 s, followed by a 300-s disso-
ciation step. After each assay cycle, the sensor surface was re-
generated with a 30-s injection of 25 mM NaOH at a ﬂow rate of
30 μL min−1. For the measurement of anti-gp140 IgG afﬁnity for
gp140 or 2-CC core (9), IgG antibodies (diluted at 20 μg mL−1 in
10 mM sodium acetate, pH 4.5) were immobilized on Series S
CM5 chips by amine coupling at a density of 1,000 RU. Re-
combinant gp140 trimer or 2-CC core were injected through ﬂow
cells at a ﬂow rate of 20 μL min−1, with the concentration
ranging from 31.25 to 1,000 nM (1:2 successive dilutions). As-
sociation time was 120 s, followed by 300 s dissociation. At the
end of each cycle, sensor surface was regenerated with 50 mM
NaOH (50 μL min−1; 30 s). Background binding to blank im-
mobilized ﬂow cells was subtracted, and afﬁnity constants were
calculated using BIAcore T100 Evaluation software using the 1:1
Langmuir binding model.
C1q Binding and C3 Fixation Assays.MouseC1q binding tomAbs and
mAb-mediated ﬁxation of mouse serum C3 were measured by
ELISA. Antibodies were serially diluted (100–0.1 μg mL−1) in PBS
and coated overnight (4 °C) onto high-binding 96-well microtiter
plates (50 μL per well). After washing with PBST [PBS + 0.05%
(vol/vol) Tween-20], plates were blocked with protein-free block-
ing buffer (Pierce). Normal mouse serum [3% (vol/vol)] was added
and incubated for 60 min with gentle shaking. For the detection of
C1q binding, biotinylated mouse monoclonal anti-C1q antibody
(JL-1, Abcam) was added at 0.5 μg mL−1, whereas for the C3 ﬁx-
ation assay, biotinylated chicken polyclonal anti-C3 antibody
(ab14232, Abcam) was used at a ﬁnal concentration of 1 μg mL−1.
Streptavidin HRP (Invitrogen) was used at a dilution of 1:2,500,
and plates were developed and analyzed as described above.
mAb Binding to Cell-Surface gp160. HEK293T cells were trans-
fected with pMX-gp160YU.2Δc-IRES-GFP (8). Mock-trans-
fected cells (carrying pMX-IRES-GFP) were used as controls.
Cells were maintained in DMEM supplemented with 10% (vol/
vol) FBS and 10 μg mL−1 puromycin. Cells were detached (5
mM EDTA in PBS), resuspended at 107/mL in PBS + 5% (vol/
vol) FBS + 2 mM EDTA, and incubated with the various anti-
gp140 mAbs (mGO53 was used as a negative control) at a ﬁnal
concentration of 20 μg mL−1 for 30 min at 4 °C. Cells were then
incubated for 20 min at 4 °C with Alexa Fluor 647-conjugated
goat anti-human IgG (1 μg mL−1; Invitrogen) and analyzed on
a BD FACSCalibur cytometer (BD Biosciences). Data were
analyzed using FlowJo (Treestar) software.
Immune Complex (IC) Binding Assay. CHO cells expressing mouse
FcγR were previously described (10). Cells were maintained in
DMEM supplemented with 10% (vol/vol) FBS and 0.1 mM
MEM nonessential amino acids with the corresponding selection
agent. ICs were generated by incubating mGO53 hIgG1 WT and
GR/LR mAb (1 mg mL−1) with Alexa Fluor 647-conjugated goat
F(ab’)2 anti-human F(ab’)2 (200 μg mL−1; Jackson Immunor-
esearch) for 20 min at 37 °C. ICs were centrifuged for 1 min at
14,000 × g to remove large aggregates, and supernatant was se-
rially diluted (100-0.1 μg mL−1 based on hIgG concentration) in
PBS +0.5% (wt/vol) IgG-free BSA (PBS-B) and immediately
used for the IC binding assay. FcγR-CHO cells were detached
using 0.01% trypsin + 5 mM EDTA and resuspended at 5 × 106
cells mL−1 in PBS-B. Cells were incubated for 30 min on ice,
washed twice with PBS-B, and IC binding was quantiﬁed using
a BD FACSCalibur cytometer (BD Biosciences). As control to
determine the speciﬁcity of the FcγR-IC interaction, cells were
preincubated with function blocking anti-FcγRII/III (2.4G2) or
anti-FcγRIV (9E9) antibodies (ﬁnal concentration 10 μg mL−1)
10 min before the addition of the ICs. Data were analyzed using
FlowJo (Treestar) software.
Statistical Analysis. Statistical analysis was performed using Prism
software (GraphPad). Statistics were calculated using an unpaired
one-tailed t test. Asterisks (*P < 0.05, **P < 0.01, ***P < 0.0001)
indicate signiﬁcant difference from the control group. Columns
and error bars represent mean ± SEM.
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Fig. S1. Antibody half-life. Antibody serum concentration in NOD Rag1−/− IL2RγNULL mice was determined by ELISA after i.v. injection of 0.5 mg antibody at
day 0. Graphs show the actual serum concentration (mean ± SEM, three mice each) of 3BNC117 (Left) and 45-46G54W (Right) plotted against the time after
monoclonal antibody injection. Dotted line indicates limit of detection. The mean half-life (t1/2) was calculated by using a one-phase exponential decay model
between day 1 and day 5–7.
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Fig. S2. Antibody Fc: hIgG1 WT vs. hIgG1 G236R/L328R. (A) Binding of hIgG1 (WT or G236R/L328R) after forming immune complexes with Alexa Fluor 647-
conjugated goat F(ab’)2 anti-human F(ab’)2 to mouse FcγRIIb, mFcγRIII, and mFcγRIV stably expressed on CHO cells. Graph shows the mean ﬂuorescent intensity
(MFI) vs. the monoclonal antibody concentration. (B and C) Binding of 3BNC60, 3BNC117, and VRC01 hIgG1 WT and GR/LR mutant to mouse C1q (B) or mouse
C3 (C) as determined by ELISA. Graph shows the absorption at 450 nm vs. the monoclonal antibody concentration.
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Fig. S3. Antibody functionality: hIgG1 WT vs. hIgG1 G236R/L328R. (A) ELISA of 3BNC60, 3BNC117, and VRC01 show comparable binding to gp140-YU2 for WT
and GR/LR. Graph shows the absorption at 450 nm vs. the monoclonal antibody concentration. (B) 3BNC60, 3BNC117, and VRC01 were tested for binding to
HIVYU-2 Env expressed on 293T cells. Binding was detected with anti-human IgG AF 647. 293T cells expressing GFP served as negative control. Representative
graph shows the MFI for the individual antibodies. (C) In vitro neutralization of HIVYU-2 by WT and GR/LR mutants of 3BNC60, 3BNC117, and VRC01, as assessed
by the TZM-bl neutralization assay. The IC50 in μg/mL against HIVYU-2 for the individual monoclonal antibodies is shown. (D) Serum antibody concentration
after 1 d, the time point of pseudovirus injection, as determined by ELISA. Graph compares the actual monoclonal antibody concentration in serum (μg/mL)
between WT and GR/LR mutant of 3BNC60, 3BNC117, and VRC01 (three to four mice per group, mean ± SEM).
Pietzsch et al. www.pnas.org/cgi/content/short/1213409109 5 of 6
Table S1. Comparison of the afﬁnities of anti-gp140 antibodies in
Fc domain variants
mAb Fc variant ka (1/Ms) kd (1/s) KD (M)
3BNC60 WT 1.4 × 104 1.73 × 10−4 1.2 × 10−8
G236R/L328R 1.36 × 104 1.79 × 10−4 1.31 × 10−8
3BNC117 WT 1.5 × 104 1.29 × 10−4 8.63 × 10−9
G236R/L328R 1.78 × 104 1.18 × 10−4 7.9 × 10−9
VRC01* WT 2.5 × 104 6.25 × 10−5 2.5 × 10−9
G236R/L328R 2.28 × 104 7.2 × 10−5 3.17 × 10−9
Afﬁnities were determined using recombinant gp140 trimer or 2-CC
core (*) and calculated by ﬁtting the SPR sensograms to the 1:1 Langmuir
binding model.
Table S2. Afﬁnities of Fc domain variants for mouse FcγR
Variable mFcγRI mFcγRIIb mFcγRIII mFcγRIV
hIgG1 WT 4.2 × 10−7 1.2 × 10−5 >10−4 9.4 × 10−7
hIgG1 G236R/L328R n.d.b. n.d.b. n.d.b. n.d.b.
n.d.b., no detectable binding.
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